Northern Trust Corp Purchases Shares of 403,031 AC Immune SA (NASDAQ:ACIU)

Northern Trust Corp bought a new stake in shares of AC Immune SA (NASDAQ:ACIU - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 403,031 shares of the company's stock, valued at approximately $1,088,000. Northern Trust Corp owned approximately 0.41% of AC Immune at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its holdings in shares of AC Immune by 14.6% in the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company's stock worth $1,999,000 after buying an additional 94,191 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of AC Immune by 130.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock valued at $355,000 after acquiring an additional 74,358 shares during the period. RPO LLC purchased a new position in AC Immune in the 4th quarter worth $51,000. Boothbay Fund Management LLC purchased a new position in AC Immune in the 4th quarter worth $38,000. Finally, Quinn Opportunity Partners LLC acquired a new stake in AC Immune during the 4th quarter worth about $27,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wall Street Zen raised AC Immune from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. HC Wainwright decreased their target price on AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, May 1st.

AC Immune Trading Up 2.0%

Shares of ACIU stock traded up $0.03 during trading hours on Friday, hitting $1.73. The company's stock had a trading volume of 73,467 shares, compared to its average volume of 164,424. The stock has a market cap of $174.10 million, a PE ratio of -3.77 and a beta of 1.62. AC Immune SA has a 12-month low of $1.43 and a 12-month high of $4.98. The company has a 50 day moving average of $1.66 and a 200 day moving average of $2.37.

AC Immune (NASDAQ:ACIU - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. The business had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.99 million. As a group, analysts anticipate that AC Immune SA will post -0.62 earnings per share for the current fiscal year.

AC Immune Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.